Q1 EPS Forecast for Wave Life Sciences Decreased by Analyst

Wave Life Sciences Ltd. (NASDAQ:WVE) – Analysts at B. Riley cut their Q1 2025 earnings per share (EPS) estimates for shares of Wave Life Sciences in a research note issued on Wednesday, March 5th. B. Riley analyst M. El-Saadi now expects that the company will post earnings per share of ($0.28) for the quarter, down from their previous forecast of ($0.25). The consensus estimate for Wave Life Sciences’ current full-year earnings is ($1.14) per share. B. Riley also issued estimates for Wave Life Sciences’ Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($0.98) EPS, FY2026 earnings at ($0.96) EPS, FY2027 earnings at ($0.20) EPS, FY2028 earnings at $0.28 EPS and FY2029 earnings at $1.05 EPS.

Wave Life Sciences (NASDAQ:WVE) last announced its quarterly earnings data on Tuesday, March 4th. The company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.34. The business had revenue of $83.75 million during the quarter, compared to the consensus estimate of $25.60 million. Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 280.57%.

Several other equities research analysts have also recently weighed in on the company. StockNews.com upgraded Wave Life Sciences from a “sell” rating to a “hold” rating in a report on Thursday, February 27th. HC Wainwright restated a “buy” rating and issued a $22.00 target price on shares of Wave Life Sciences in a research note on Wednesday. Mizuho boosted their price target on Wave Life Sciences from $19.00 to $22.00 and gave the stock an “outperform” rating in a research note on Thursday, November 21st. Jefferies Financial Group began coverage on shares of Wave Life Sciences in a report on Tuesday, February 25th. They set a “buy” rating and a $26.00 price objective on the stock. Finally, Truist Financial increased their price target on shares of Wave Life Sciences from $17.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday, November 12th. Two investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $22.60.

Wave Life Sciences Price Performance

Wave Life Sciences stock opened at $9.40 on Friday. The stock has a market cap of $1.43 billion, a price-to-earnings ratio of -8.47 and a beta of -1.09. The firm has a 50-day moving average of $11.44 and a two-hundred day moving average of $11.21. Wave Life Sciences has a 1 year low of $4.25 and a 1 year high of $16.74.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Victory Capital Management Inc. lifted its stake in shares of Wave Life Sciences by 16.6% in the fourth quarter. Victory Capital Management Inc. now owns 14,546 shares of the company’s stock worth $180,000 after buying an additional 2,073 shares in the last quarter. Summit Investment Advisors Inc. boosted its holdings in shares of Wave Life Sciences by 31.5% during the 4th quarter. Summit Investment Advisors Inc. now owns 9,642 shares of the company’s stock worth $119,000 after purchasing an additional 2,308 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Wave Life Sciences in the fourth quarter valued at approximately $40,000. Kraematon Investment Advisors Inc. increased its holdings in shares of Wave Life Sciences by 24.3% in the fourth quarter. Kraematon Investment Advisors Inc. now owns 19,885 shares of the company’s stock valued at $246,000 after purchasing an additional 3,885 shares during the last quarter. Finally, Pictet Asset Management Holding SA lifted its position in Wave Life Sciences by 36.0% during the fourth quarter. Pictet Asset Management Holding SA now owns 15,579 shares of the company’s stock worth $193,000 after buying an additional 4,120 shares in the last quarter. Hedge funds and other institutional investors own 89.73% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Paul Bolno sold 169,025 shares of Wave Life Sciences stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $9.57, for a total value of $1,617,569.25. Following the sale, the chief executive officer now directly owns 338,351 shares of the company’s stock, valued at $3,238,019.07. The trade was a 33.31 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 29.10% of the stock is currently owned by company insiders.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.